The Role of SGLT-1 Inhibitors in Weight Management for Diabetic Patients

References

[1] Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA's assessment of two drugs for chronic weight management. N Engl J Med. 2012;367:1577-1579.

[2] Hjorth MF, Zohar Y, Hill JO, Astrup A. Personalized dietary management of overweight and obesity based on measures of insulin and glucose. Annu Rev Nutr. 2018;38:245-272.

[3] Fiorentino TV, Suraci E, Arcidiacono GP, et al. Duodenal sodium/glucose cotransporter 1 expression under fasting conditions is associated with Postload hyperglycemia. J Clin Endocrinol Metab. 2017;102:3979-3989.

[4] . Nguyen NQ, Debreceni TL, Bambrick JE, et al. Accelerated intestinal glucose absorption in morbidly obese humans: relationship to glucose transporters, incretin hormones, and glycemia. J Clin Endocrinol Metab. 2015;100:968-976.

[5] Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1730-1735.

[6] Buse JB, Garg SK, Rosenstock J, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study. Diabetes Care. 2018;41:1970-1980.

[7] . Garg SK, Henry RR, Banks P, et al. Effects of Sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377:2337-2348.

[8] Rosenstock J, Cefalu WT, Lapuerta P, et al. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes Care. 2015;38:431-438.

[9] DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017; 13:11-26.

[10] Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515-531.

[11] Abdul-Ghani MA, Norton L, DeFronzo RA. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep. 2012;12:230-238.

[12] Vrhovac I, Balen Eror D, Klessen D, et al. Localizations of Na(+)-Dglucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch. 2015;467:1881-1898.

[13] . Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733-794.

[14] Turk E, Zabel B, Mundlos S, Dyer J, Wright EM. Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature. 1991;350:354-356.

[15] Ezcurra M, Reimann F, Gribble FM, Emery E. Molecular mechanisms of incretin hormone secretion. Curr Opin Pharmacol. 2013;13: 922-927.

[16] Holzer P, Reichmann F, Farzi A. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. Neuropeptides. 2012;46: 261-274.

[17] Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012; 344:d7771.

[18] . Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012;92:158-169

[19] Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodiumdependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011;13:1219-1227.

[20] Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with typePharmacol Ther. 2009;85:513-519.

[21] Powell DR, Smith M, Greer J, et al. LX4211 increases serum glucagonlike peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013;345:250-259.

[22] ñäÙÌ´©šƒoƒƒƒ[F-0hK)h4çB*CJOJPJQJ\�^JaJph(h4çhK)5�6�CJOJQJ\�]�aJ&hòÛ5�6�CJOJPJQJ\�]�aJ&hK)5�6�CJOJPJQJ\�]�aJ,h4çhòÛ5�6�CJOJPJQJ\�]�aJh^~ h˜gCJOJQJaJhòÛh^~ OJQJhK)hK)6�OJQJ]�h^~ OJPJQJhòÛhiOJPJQJh^~ h^~ OJQJhK)h^~ CJ(OJQJhòÛhòÛCJ(OJPJQJIJ^stuf [Some characters in this reference could not be displayed correctly — please refer to the published PDF for the full reference.]

[23] [Some characters in this reference could not be displayed correctly — please refer to the published PDF for the full reference.]

@article{1708509,
      author = {Khashayar Mohammadi},
      title = {The Role of SGLT-1 Inhibitors in Weight Management for Diabetic Patients },
      journal = {Iconic Research And Engineering Journals},
      year = {2025},
      volume = {8},
      number = {11},
      pages = {1866-1875},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1708509.pdf},
      abstract = {Sodium glucose co-transporter-1 inhibitors were initially used to treat type-2 diabetes but have now emerged as potential candidates in the field of weight management in diabetic patients. The inhibitors when blocking the SGLT-1 transporter in the jejunum and ileum decrease the absorption of glucose conversely, stimulation of a higher excretion of glucose via urine. When considered an extremely important player in the glycemic control, it is equally important in beings an agent of weight reduction. Weight reduction is vital for metabolic control and minimization of complications since obesity is one of the known comorbidities affecting type-2 diabetic patients. Weight loss elicited by SGLT-1 inhibitors is believed to involve mechanisms other than glucose regulation, including appetite suppression and elevation of insulin sensitivity. This article will discuss how SGLT-1 inhibitors pharmacologically impact body weight and put in perspective mechanisms that should be made pertinent in weight loss for diabetic patients in clinical practice. Further, we shed light on the safety aspect of SGLT-1 inhibitors and equip readers with inputs for consideration with regard to their role in integrated weight management strategies for diabetes care.},
      month = {May},
  }